Back to search results
NCT05957913

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Enrolling by Invitation
PHASE2Ages 18+InterventionalBasic science
Massachusetts General Hospital
~50 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:Truvada (tenofovir/emtricitabine)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Epstein Barr virus (EBV) viral load
Measured over Change from baseline at three months

Conditions

Multiple Sclerosis

Explore related trials

Multiple SclerosisX-linked Lymphoproliferative Syndrome 1

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Michael Levy, MD, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of signed and dated informed consent form
Stated willingness and ability to comply with all study procedures and availability for the duration of the study
Age: 18+
Established diagnosis of multiple sclerosis
Evidence of Epstein Barr virus (EBV) infection by serological testing for EBV antibodies antibodies (subjects will have EBV testing performed at the pre-screening visit and if serologies are negative, the subjects will be removed from the study)

Exclusion

Pregnancy or lactation
Known allergic reactions to components of Truvada
Previous treatment with Truvada or Descovy
Unknown HIV status (subjects must have completed HIV antigen/antibody and viral load testing within the prior 6 months to being enrolled or have the testing completed at the pre-screening visit)
Active or latent hepatitis B (HBV) (subjects must have completed HBV serologies - HbsAg, anti-HBs, and anti-HBc - within the prior 6 months to being enrolled or have the testing completed at the pre-screening visit)
Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study
Creatinine clearance (CrCl) \<75mL/min, as calculated by the Cockcroft-Gault equation
Urine dipstick for protein and glucose, excluding values of "1 +" or greater
Any history of bone fractures not explained by trauma
Confirmed Grade 2 or greater hypophosphatemia
Any Grade 2 or greater toxicity on screening tests and assessments
Taking a medication with known interactions with Truvada including but not limited to: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple non-steroidal antiinflammatories (NSAIDs) or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect renal function
Current treatment with drugs known to affect EBV replication as listed below: Acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, interferon

What this trial measures

  • Epstein Barr virus (EBV) viral loadChange from baseline at three months

    EBV viral load will be quantified in saliva and peripheral blood using a sensitive assay.